Cian Healthcare Limited has revised the record date for the reduction, cancellation, and extinguishment of its existing paid-up share capital from January 16, 2026, to January 21, 2026. The revision was communicated to BSE Limited through a regulatory filing dated January 12, 2025, in compliance with Regulation 37 and 42 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

NCLT Order Implementation

The share capital restructuring follows an order from the Hon'ble National Company Law Tribunal, Mumbai, Bench-VI, dated December 18, 2025. The company's Resolution Plan Implementation Committee meeting held on January 09, 2026, resulted in the decision to revise the previously announced record date of January 16, 2026.

Share Capital Restructuring Details

The restructuring involves two distinct categories of shareholders with different treatment mechanisms:

Promoter Shareholding Extinguishment

The existing promoter shareholding of 67,74,897 equity shares, representing 27.10% of the total paid-up share capital, will be completely reduced, cancelled, and extinguished without any consideration. The estimated liquidation value of the promoter shareholding has been determined as nil, justifying the zero consideration approach.

Public Shareholder Treatment

Public shareholders holding 1,82,20,867 equity shares will have their existing holdings reduced and cancelled. However, they will receive 12,50,000 fresh equity shares with a face value of ₹10.00 each, issued in proportion to their shareholding as recorded on January 21, 2026.

Regulatory Compliance

The communication was signed by Roshen Chordiya, Chairman of the Resolution Plan Implementation Committee and former Resolution Professional of Cian Healthcare Limited. The filing ensures compliance with the Insolvency and Bankruptcy Code, 2016, alongside the SEBI listing regulations and the specific NCLT order provisions.

Cian Healthcare Limited has announced significant board changes following the approval of its resolution plan by the National Company Law Tribunal (NCLT). The company disclosed the appointment of four new directors to its interim board, marking a crucial step in its corporate restructuring process under the Insolvency and Bankruptcy Code, 2016.

Resolution Plan Implementation Committee Approves New Board

The Resolution Plan Implementation Committee, in its meeting held on January 09, 2026, from 03:00 P.M. to 3:46 P.M. (IST) through video conferencing, considered and approved the nomination and appointment of the new board members. This decision follows the NCLT order dated December 18, 2025, which approved the resolution plan submitted by the Successful Resolution Applicant, Mr. Pradeep Kumar Jain.

The newly appointed directors and their designations are:

Board Powers and Implementation Timeline

The interim board's powers will remain suspended during the Resolution Plan Implementation Period, which commenced from the date of the NCLT Order and will continue until the Resolution Plan Closure Date. During this period, all board powers will be exercised by the Implementation Committee in accordance with the NCLT Order provisions.

Upon reaching the Resolution Plan Closure Date, the interim board will be granted full powers under the Companies Act, 2013, Listing Regulations, and other applicable regulatory provisions. Subsequently, the Implementation Committee will cease to have authority over the interim board.

Director Profiles and Qualifications

Mr. Pradeep Kumar Jain, appointed as Promoter and Non-Executive Director effective January 09, 2026, brings over 25 years of pharmaceutical industry experience. He holds a bachelor's degree in production management from the National Technical University "Kharkiv Polytechnic Institute" and an MBA followed by a PhD from Simon Kuznets Kharkiv National University of Economics. He has been instrumental in establishing Ananta Medicare Limited's operations and driving international expansion in Eastern Europe and CIS markets.

Mr. Rajesh Jain, also appointed as Promoter and Non-Executive Director from January 09, 2026, specializes in project management and production optimization within the pharmaceutical industry. He holds a Master of Pharmacy from Punjab Technical University (2013) and a Bachelor of Pharmacy from the University of Rajasthan (1995), while currently pursuing a PhD. His professional experience spans pharmaceuticals, retail, wholesale, manufacturing, laboratory services, and marketing since 1995.

Mr. Manish Goswami assumes the role of Independent Non-Executive Director for a five-year term starting January 09, 2026. With over two decades of pharmaceutical industry experience, he is a registered Vaidya with the Punjab Ayurvedic and Unani Systems of Medicine Board. He holds a PhD from North Gujarat University, focusing on "Studies and Design of Transdermal Drug Delivery Systems for Antiasthmatics," and has served as Director at the University Institute of Pharma Sciences and University Institute of Allied Health Sciences.

Mr. Anjani Misra joins as Independent Non-Executive Director for a five-year term from January 09, 2026. He brings 26 years of experience from the Reserve Bank of India, where he served as General Manager for over a decade. His expertise includes Rural Planning and Credit, Department of Supervision oversight, and serving as compounding authority under the Foreign Exchange Management Act, 1999.

Regulatory Compliance and Disclosures

The company confirmed that none of the proposed directors are debarred from holding directorship positions by SEBI or any other regulatory authority. The appointments comply with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, along with relevant SEBI circulars and the Companies Act, 2013.

Mr. Pradeep Kumar Jain and Mr. Rajesh Jain are disclosed as relatives under Section 2(77) of the Companies Act, 2013, and Regulation 2(zd) of the SEBI Listing Regulations. The other two independent directors have no disclosed relationships with existing board members.